Abstract 611P
Background
The ESMO-MCBS provides a standardized assessment of the clinical benefit of a study treatment, considering factors such as overall survival and quality of life. We examined the profile of scores for trials of adjuvant therapy or potentially curative therapies presented at ASCO22 to assess the applicability of the MCBS.
Methods
Abstracts and prior or subsequent (until April 10, 2023) full publications of phase 3 trials on adjuvant therapy or curative treatment presented at ASCO22 were assessed using the MCBS v1.1 evaluation form 1. Scores were calculated based on overall survival, disease free survival or pathological complete response data and graded as A, B or C. Grades A and B indicate a substantial magnitude of clinical benefit. Two independent reviewers performed the grading; discrepancies were resolved through discussion and consensus with a third investigator.
Results
Thirty-five trials were evaluated, of which 11 could not be scored due to insufficient data or endpoint not gradable of the remaining 24 trials, 12 could not be graded due to statistically non-significant results. The remaining 12 trials were scored based on abstract alone (n= 6), or subsequent publication (n=6). A meaningful clinical benefit was seen in 11 of 12 trials (92%) with a score of A (n=9) or B (n=2), whereas 1 study had a score C.
Conclusions
Applying the current ESMO-MCBS to adjuvant and curative phase 3 trials presented at ASCO22 has significant limitations, due to the number of trials not able to be scored. This is a particular problem for studies with non-significant results. Adapting the score to allow grading of all trials may better assist clinicians and patients to assess the value of contemporary research.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
E. Segelov: Non-Financial Interests, Personal, Member: ESMO-MCBS Working Group. All other authors have declared no conflicts of interest.
Resources from the same session
506P - Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: Implications for thoracic radiotherapy
Presenter: Byoung Hyuck Kim
Session: Poster Display
Resources:
Abstract
519P - Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in first-line treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC)
Presenter: Ying Cheng
Session: Poster Display
Resources:
Abstract
520P - Role of atezolizumab in controlling CNS progression in ES-SCLC
Presenter: Yoon Namgung
Session: Poster Display
Resources:
Abstract
521P - Camrelizumab combined with chemotherapy and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory research
Presenter: Yanbin Zhao
Session: Poster Display
Resources:
Abstract
522P - Durvalumab plus etoposide and carboplatin for extensive-stage small cell lung cancer with mild idiopathic interstitial pneumonia
Presenter: Ichiro Nakachi
Session: Poster Display
Resources:
Abstract
523P - Camrelizumab plus apatinib as maintenance treatment in patients with extensive-stage small cell lung cancer who were responding or stable after standard first-line chemotherapy (CAMERA): Results from a single-arm, phase II trial
Presenter: Qi Wang
Session: Poster Display
Resources:
Abstract
524P - Treatment pattern and overall survival by lines of therapy among patients with advanced small cell lung cancer in Taiwan
Presenter: Kelly Huang
Session: Poster Display
Resources:
Abstract
525P - Development of diagnostic prediction score for malignant pleural effusion in lung cancer: MPE-Lung score
Presenter: Chaichana Chantharakhit
Session: Poster Display
Resources:
Abstract
526P - Burden and trends of tracheal, bronchus, and lung (TBL) cancer in Southeast Asia, East Asia, and Oceania from 1990-2019, and its projection of deaths to 2040: A benchmarking analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
527P - Efficacy of intraventricular chemotherapy with pemetrexed for leptomeningeal metastasis from lung adenocarcinoma: A retrospective study
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract